German Commercial Services Stock News

If you are wondering whether Deutsche Bank's current share price gives you good value for your money, you are not alone. This article focuses squarely on what you might be paying for each euro of underlying business. After a 1.5% move over the last week, 1.8% over the past month, flat year to date and an 86.2% return over the past year, Deutsche Bank's share price invites a closer look at what is baked into expectations. Recent coverage has highlighted Deutsche Bank's ongoing efforts to...

Sales update puts Redcare Pharmacy in focus Redcare Pharmacy (XTRA:RDC) is back on investors’ radar after reporting fourth quarter 2025 group sales of €794 million, compared with €675 million a year earlier, alongside full year sales of €2.9b versus €2.4b in 2024. See our latest analysis for Redcare Pharmacy. Despite the strong sales update, Redcare Pharmacy’s share price has had a weak run, with a 90 day share price return of 24.46% decline and a 1 year total shareholder return of 45.89%...

While CTS Eventim AG & Co. KGaA ( ETR:EVD ) might not have the largest market cap around , it saw significant share...

There are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...

BRAIN Biotech AG ( ETR:BNN ) is possibly approaching a major achievement in its business, so we would like to shine...

With a price-to-earnings (or "P/E") ratio of 37.2x Knorr-Bremse AG ( ETR:KBX ) may be sending very bearish signals at...

It's shaping up to be a tough period for BRAIN Biotech AG ( ETR:BNN ), which a week ago released some disappointing...

Investing in stocks inevitably means buying into some companies that perform poorly. Long term PNE AG ( ETR:PNE3...

If you are wondering whether Mercedes-Benz Group is attractively priced right now, this article walks through what the current share price really reflects. The stock closed at €58.82, with returns of a 2.6% decline over 7 days, a 1.7% decline over 30 days, a 5.0% decline year to date, a 16.0% return over 1 year, 13.2% over 3 years and 65.6% over 5 years. This gives you a mix of shorter term weakness and longer term gains to think about. Recent coverage around Mercedes-Benz Group has focused...

At Cosmet’Agora 2026 in Paris, BASF’s Personal Care business showcased its Beyond Beauty vision by launching new hybrid formulation concepts and unveiling two ingredients, Aloversil™ for men’s hair density support and Dehyquart® S18, a biodegradable conditioning agent for haircare. An interesting angle is how BASF is pairing performance claims with sustainability credentials, using upcycled sea buckthorn byproducts and readily biodegradable chemistry to align cosmetics innovation with...

Recent coverage indicates that Bechtle AG’s AI-related services are helping drive higher-margin projects and growing recurring managed-service bookings across its European customer base. This shift toward AI-enabled, service-based work highlights how Bechtle may be reshaping its revenue mix toward more resilient, contract-driven income streams. Next, we’ll examine how rising AI-driven, higher-margin managed-service demand could influence Bechtle’s existing investment narrative and risk...

Redcare Pharmacy NV recently reported its fourth-quarter 2025 sales of €794 million, up from €675 million a year earlier, with full-year 2025 sales rising to €2.90 billion from €2.40 billion in 2024. This sales expansion underscores how Redcare Pharmacy is scaling its online pharmacy operations across Europe, reinforcing its position in the digital healthcare market. We’ll now examine how this step-up in annual sales reshapes Redcare Pharmacy’s investment narrative, especially around revenue...

Südzucker AG has reported past third-quarter 2025 results showing sales of €2,156 million, down from €2,374 million a year earlier, while net income improved to €3 million from a net loss of €119 million and basic loss per share from continuing operations narrowed to €0.02 from €0.62. Over the first nine months, sales fell to €6,355 million from €7,466 million and the company moved from €23 million net income to a €59 million net loss, highlighting that the recent quarterly profit comes...

Why Fresenius Medical Care Stock Is Back in Focus Fresenius Medical Care (XTRA:FME) has grabbed investor attention after confirming it expects to hit the top end of its 2025 revenue growth range and projecting high-teens to high-20s operating income growth. See our latest analysis for Fresenius Medical Care. Despite the upbeat 2025 guidance and progress in home hemodialysis, Fresenius Medical Care’s recent trading has been choppy. The 1 day share price return was 1.46% to €37.47 after a sharp...

Nordex (XTRA:NDX1) has been in focus after securing a series of sizeable turbine orders across Spain, France, Belgium, Portugal, and Canada, many paired with long-term service agreements that extend revenue visibility. See our latest analysis for Nordex. These fresh turbine contracts arrive after a strong run in the stock, with a 90 day share price return of 38.89% and a 1 year total shareholder return of 164.96%, suggesting momentum has recently been building. If Nordex's recent contract...

In early January 2026, Bayerische Motoren Werke AG continued its 2025–2027 share buy-back programme, repurchasing 390,000 ordinary shares across venues such as Xetra and CBOE Europe, with detailed transaction data disclosed on the company’s website. More recently, BMW responded to a 10.4% China sales decline and a much sharper New Energy Vehicle drop by cutting prices on 31 key models by up to 24% and accelerating local partnerships to reinforce its position in the world’s largest auto...

Key Insights IONOS Group's estimated fair value is €49.15 based on 2 Stage Free Cash Flow to Equity IONOS Group is...

CropEnergies (HMSE:CE2) has drawn fresh attention after recent price moves, with the share last closing at €13.65. For investors, the key question now is how this aligns with its current valuation. See our latest analysis for CropEnergies. Recent share price moves for CropEnergies have been fairly muted, with a 90 day share price return of 0.66% and a year to date share price return of 0.36% decline. The 1 year total shareholder return is close to flat, which suggests momentum is currently...

Key Insights Insiders appear to have a vested interest in Serviceware's growth, as seen by their sizeable ownership A...

PAL Next AG ( ETR:PAL ) is possibly approaching a major achievement in its business, so we would like to shine some...

You may think that with a price-to-sales (or "P/S") ratio of 0.4x Blue Cap AG ( ETR:B7E ) is definitely a stock worth...

When close to half the companies operating in the Communications industry in Germany have price-to-sales ratios (or...

Earlier this week, Fresenius Kabi and TQ Therapeutics announced a development agreement giving Fresenius Kabi exclusive rights to integrate TQ’s proprietary cell selection technology into its Cue Cell Processing System for automated, high‑purity T cell isolation in cell and gene therapy manufacturing. This collaboration could materially enhance Fresenius’s position in advanced therapies by pairing TQ’s affinity-based cell isolation with Fresenius Kabi’s automation capabilities, potentially...